Tempus AI Poised for Recovery Following Nearly 50% Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TEM?
Source: Marketbeat
Stock Performance: Tempus AI shares have experienced significant volatility since their public offering, initially priced at $37, peaking at $85 by February 2025, before dropping to around $54, nearly 50% below their all-time high.
Financial Results: The company reported an 83% revenue growth to $367 million in Q4 2025, although much of this growth was attributed to acquisitions, with organic growth at 33.5%. Adjusted earnings improved to $12.9 million from a loss of $7.8 million in the previous year.
Market Position: Tempus is seeing strong demand for its offerings, with a net retention rate of 126% for the full year, indicating existing customers are increasing their spending significantly.
Future Outlook: Analysts suggest that Tempus has a substantial opportunity for rebound, with price targets suggesting over 40% upside potential, and the company is expected to grow revenues by 25% in 2026, with a projected EBITDA of $65 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 51.400
Low
76.00
Averages
84.38
High
105.00
Current: 51.400
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus AI Partners with Merck for AI-Driven Precision Medicine
- Strategic Collaboration: Tempus AI has signed a strategic collaboration agreement with Merck aimed at accelerating AI-driven precision medicine, leveraging Tempus' multimodal data library and advanced Lens platform to enhance the discovery and development of precision medicine biomarkers.
- Market Impact: Despite the strategic significance of the partnership with Merck, Tempus' stock is under pressure due to broader market declines, with the S&P 500 and Nasdaq falling by 1.78% and 2.18%, respectively, indicating the influence of market sentiment on individual stocks.
- Financial Performance: In its latest earnings report, Tempus reported a quarterly loss of four cents per share, in line with expectations, while quarterly revenue reached $367.21 million, exceeding the Street estimate of $362.29 million and representing an 83% increase from $200.68 million in the prior year.
- Technical Analysis: Tempus' stock is currently trading 9.8% below its 100-day simple moving average, indicating potential weakness in the long-term trend, with an RSI of 44.45 suggesting neutral market conditions, and a MACD of 0.15 below its signal line of 0.22 indicating bearish pressure.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
Tempus and Merck Expand Collaboration to Advance Precision Medicine
- Collaboration Expansion: Tempus AI and Merck have announced a multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers, further solidifying their partnership in multimodal data and AI.
- Platform Utilization: Merck will leverage Tempus' de-identified data and Lens Platform, utilizing one of the industry's largest GPU infrastructures to conduct complex analyses, thereby enhancing the efficiency of candidate therapy development and advancing precision oncology.
- AI Technology Transformation: The integration of new technologies enables researchers to quickly identify mechanisms of cancer cell resistance and provide rational bases for drug combinations in early pipelines, significantly increasing the success rate and efficiency of drug development.
- Market Outlook: Tempus aims to leverage its extensive multimodal data library to provide personalized patient care solutions for physicians, which is expected to drive the widespread application of precision medicine and improve patient treatment outcomes.
See More
TEMPUS AI INC AND MERCK UNVEIL LONG-TERM PARTNERSHIP
Announcement of Collaboration: Tempus AI Inc. and Merck have announced a multi-year collaboration aimed at advancing healthcare solutions.
Focus on Innovation: The partnership will focus on leveraging artificial intelligence and data analytics to enhance patient care and treatment outcomes.
See More
TEMPUS AND MERCK FORM STRATEGIC PARTNERSHIP TO ADVANCE AI-DRIVEN PRECISION MEDICINE
Strategic Collaboration Announcement: Tempus has announced a strategic collaboration agreement with Merck to enhance precision medicine through AI-driven solutions.
Focus on Precision Medicine: The partnership aims to accelerate advancements in precision medicine, leveraging AI technology to improve patient outcomes.
See More
Tempus AI Partners with Merck for AI-Driven Precision Medicine
- Strategic Collaboration: Tempus AI has signed a strategic collaboration agreement with Merck aimed at accelerating AI-driven precision medicine, leveraging Tempus' multimodal data library and advanced Lens platform to enhance the discovery and development of precision medicine biomarkers.
- Market Impact: Despite the strategic significance of the partnership with Merck, Tempus' stock is under pressure due to broader market declines, with the S&P 500 and Nasdaq falling by 1.78% and 2.18%, respectively, indicating the influence of market sentiment on individual stocks.
- Financial Performance: In its latest earnings report, Tempus reported a quarterly loss of four cents per share, in line with expectations, while quarterly revenue reached $367.21 million, exceeding the Street estimate of $362.29 million and representing an 83% increase from $200.68 million in the prior year.
- Technical Analysis: Tempus' stock is currently trading 9.8% below its 100-day simple moving average, indicating potential weakness in the long-term trend, with an RSI of 44.45 suggesting neutral market conditions, and a MACD of 0.15 below its signal line of 0.22 indicating bearish pressure.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
Tempus and Merck Expand Collaboration to Advance Precision Medicine
- Collaboration Expansion: Tempus AI and Merck have announced a multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers, further solidifying their partnership in multimodal data and AI.
- Platform Utilization: Merck will leverage Tempus' de-identified data and Lens Platform, utilizing one of the industry's largest GPU infrastructures to conduct complex analyses, thereby enhancing the efficiency of candidate therapy development and advancing precision oncology.
- AI Technology Transformation: The integration of new technologies enables researchers to quickly identify mechanisms of cancer cell resistance and provide rational bases for drug combinations in early pipelines, significantly increasing the success rate and efficiency of drug development.
- Market Outlook: Tempus aims to leverage its extensive multimodal data library to provide personalized patient care solutions for physicians, which is expected to drive the widespread application of precision medicine and improve patient treatment outcomes.
See More
TEMPUS AI INC AND MERCK UNVEIL LONG-TERM PARTNERSHIP
Announcement of Collaboration: Tempus AI Inc. and Merck have announced a multi-year collaboration aimed at advancing healthcare solutions.
Focus on Innovation: The partnership will focus on leveraging artificial intelligence and data analytics to enhance patient care and treatment outcomes.
See More
TEMPUS AND MERCK FORM STRATEGIC PARTNERSHIP TO ADVANCE AI-DRIVEN PRECISION MEDICINE
Strategic Collaboration Announcement: Tempus has announced a strategic collaboration agreement with Merck to enhance precision medicine through AI-driven solutions.
Focus on Precision Medicine: The partnership aims to accelerate advancements in precision medicine, leveraging AI technology to improve patient outcomes.
See More
